Editas up as Stifel upgrades to 'buy' on sickle cell therapy progress

Editas Medicine

29/09/2023 13:17

** Shares of Editas Medicine  EDIT.O  rise 9.8% to $7.60
premarket
    ** Stifel upgrades EDIT to "buy" rating from "hold", raises
price target to $17 from $9
    ** Brokerage says the gene editing co's sickle cell therapy
progress has received 'minimal credit' from investors
    ** Adds that it is "challenging" to rationalize the mismatch
between EDIT and rival CRISPR Therapeutics'  CRSP.BN  valuations
    
    ** CRSP's therapy for sickle cell disease was granted
priority review in June
    ** Sickle cell disease is an inherited blood disorder that
affects hemoglobin, the protein that carries oxygen through the
body
    ** Up to last close, shares down 22% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))